SK73794A3 - Stabilized pharmaceutical formulation comprising growth hormone and aspargine - Google Patents

Stabilized pharmaceutical formulation comprising growth hormone and aspargine Download PDF

Info

Publication number
SK73794A3
SK73794A3 SK737-94A SK73794A SK73794A3 SK 73794 A3 SK73794 A3 SK 73794A3 SK 73794 A SK73794 A SK 73794A SK 73794 A3 SK73794 A3 SK 73794A3
Authority
SK
Slovakia
Prior art keywords
growth hormone
hgh
asparagine
deamidation
preparation
Prior art date
Application number
SK737-94A
Other languages
English (en)
Slovak (sk)
Inventor
Hans Sorensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of SK73794A3 publication Critical patent/SK73794A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SK737-94A 1991-12-20 1992-12-16 Stabilized pharmaceutical formulation comprising growth hormone and aspargine SK73794A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK912047A DK204791D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
PCT/DK1992/000378 WO1993012811A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and asparagine

Publications (1)

Publication Number Publication Date
SK73794A3 true SK73794A3 (en) 1995-03-08

Family

ID=8109696

Family Applications (1)

Application Number Title Priority Date Filing Date
SK737-94A SK73794A3 (en) 1991-12-20 1992-12-16 Stabilized pharmaceutical formulation comprising growth hormone and aspargine

Country Status (19)

Country Link
US (2) US5977069A (de)
EP (1) EP0618806B1 (de)
JP (1) JP3662580B2 (de)
KR (1) KR100270726B1 (de)
AT (1) ATE177645T1 (de)
AU (1) AU664416B2 (de)
BG (1) BG98804A (de)
CA (1) CA2125856A1 (de)
CZ (1) CZ282826B6 (de)
DE (1) DE69228704T2 (de)
DK (1) DK204791D0 (de)
FI (1) FI942905L (de)
HU (1) HUT69682A (de)
NO (1) NO942299D0 (de)
NZ (1) NZ246555A (de)
RO (1) RO112086B1 (de)
RU (1) RU2098130C1 (de)
SK (1) SK73794A3 (de)
WO (1) WO1993012811A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
EP0805689A1 (de) * 1995-01-13 1997-11-12 Novo Nordisk A/S Stabilisierte pharmazeutische zubereitung, welche ein wachstumshormon und x-lys enthält
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
NZ310644A (en) * 1995-06-07 1999-08-30 Alkermes Inc Composition for sustained release of human growth hormone
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
JP4060884B2 (ja) * 1995-08-28 2008-03-12 昭和薬品化工株式会社 局所麻酔用組成物
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
TWI283182B (en) * 2000-08-07 2007-07-01 Nektar Therapeutics Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
WO2002092619A2 (en) * 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
RU2234945C2 (ru) * 2002-10-15 2004-08-27 Вардосанидзе Ирина Викторовна Стабилизатор водного раствора и водосодержащего сырья с самопроизвольно изменяющимися окислительно-восстановительными свойствами
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP2099496A2 (de) * 2006-12-08 2009-09-16 Massachusetts Institute of Technology Freisetzung von nanopartikeln und/oder wirkstoffen in zellen
US20160015789A1 (en) * 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
EP0303746B2 (de) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilisierung von Wachstumshormonen
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5122512A (en) * 1988-09-12 1992-06-16 Pitman-Moore, Inc. Swine growth promoting composition
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
DK0618807T3 (da) * 1991-12-20 2003-03-03 Novo Nordisk As Stabiliseret farmaceutisk formulering omfattende human væksthormon og histidin
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ES2153385T5 (es) * 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation

Also Published As

Publication number Publication date
FI942905A7 (fi) 1994-06-17
DE69228704D1 (de) 1999-04-22
FI942905A0 (fi) 1994-06-17
ATE177645T1 (de) 1999-04-15
KR940703689A (ko) 1994-12-12
JPH07502515A (ja) 1995-03-16
WO1993012811A1 (en) 1993-07-08
EP0618806B1 (de) 1999-03-17
BG98804A (bg) 1995-02-28
CA2125856A1 (en) 1993-07-08
FI942905L (fi) 1994-06-17
US5977069A (en) 1999-11-02
AU664416B2 (en) 1995-11-16
RU94045921A (ru) 1996-08-27
JP3662580B2 (ja) 2005-06-22
HUT69682A (en) 1995-09-28
NZ246555A (en) 1996-03-26
NO942299L (no) 1994-06-17
CZ145894A3 (en) 1994-12-15
EP0618806A1 (de) 1994-10-12
DK204791D0 (da) 1991-12-20
DE69228704T2 (de) 1999-09-16
NO942299D0 (no) 1994-06-17
RO112086B1 (ro) 1997-05-30
RU2098130C1 (ru) 1997-12-10
HU9401831D0 (en) 1994-09-28
AU3344593A (en) 1993-07-28
KR100270726B1 (ko) 2000-11-01
US5851992A (en) 1998-12-22
CZ282826B6 (cs) 1997-10-15

Similar Documents

Publication Publication Date Title
SK73794A3 (en) Stabilized pharmaceutical formulation comprising growth hormone and aspargine
AU733592B2 (en) A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent
AU715997B2 (en) A stabilized pharmaceutical formulation comprising a growth hormone pre-treated with zinc and optionally lysine or calcium ions
US5705482A (en) Pharmaceutical formulation
US5654278A (en) Composition and method comprising growth hormone and leucine
CZ150794A3 (en) Pharmaceutical preparation containing growth hormone and histidine
US5631225A (en) Pharmaceutical formulation
US8841252B2 (en) Pharmaceutical formulation
US5547696A (en) Pharmaceutical formulation
EP0785797B1 (de) Ein wachstumshormon und leucin enthaltende pharmazeutische formulierung
US5552385A (en) Pharmaceutical formulation
US6022858A (en) Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
AU699850B2 (en) A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least, one basic amino acid residue and at least one acid amino acid residue
US20030162711A1 (en) Pharmaceutical formulation
MXPA98000309A (en) Stabilized pharmaceutical formulation comprising a hormone of growth and a peptide that comprises at least one residue of basic amino acid and at least one waste of aminoacido ac
MXPA98008786A (en) A pharmaceutical formulation containing a growth hormone, an amino acid and a non-ion detergent
MXPA98000358A (en) Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal